Professor James Lindsay, FRCP PhD BM BCh
Professor of Inflammatory Bowel Disease
Email: James.email@example.com Telephone: 020 3594 3300 (RLH) 020 7882 7191 (QMUL)
James Lindsay is the Professor of Inflammatory Bowel Disease at Barts and the London School of Medicine and Dentistry, Queen Mary University of London and a Consultant Gastroenterologist at Barts Health NHS Trust. Along with a full multidisciplinary team he runs the adolescent and adult IBD service at The Royal London Hospital. He is the Education Officer and a member of the Governing Board of the European Crohn’s and Colitis Organisation (ECCO). He is also the ECCO e-learning ambassador and past chair of the ECCO Education Committee. He has chaired working groups for the ECCO consensus on the management of Crohn’s disease and ulcerative colitis. He is the British Society of Gastroenterology (BSG) national societies representative to United European Gastroenterology.
Professor James Lindsay is Consultant Gastroenterologist at Barts Health NHS Trust and Reader in Inflammatory Bowel Disease at Barts and the London School of Medicine.
Along with a full multidisciplinary team he runs the adolescent and adult IBD service at The Royal London Hospital.
Professor Lindsay is the IBD module director for the MSC in Gastroenterology
Professor Lindsay serves on the BSG IBD Clinical Trials Steering Group and is Chief Investigator for a series of investigator-led and commercial clinical trials in IBD. He leads the NIHR funded ASTIClite trial which will assess the efficacy, safety and mechanism of action of low intensity autologous stem cell transplantation in patients with refractory Crohn’s disease. In addition, he jointly supervises two translational research programmes: one focusing on antigen presentation and cell trafficking within the mucosal immune system (in collaboration with Dr Andy Stagg), and the other studying the role of microRNA profiles to direct phenotype in IBD (in collaboration with Prof Andy Silver).
Rossi M, Aggio R, Staudacher HM, Lomer MC, Lindsay JO, Irving P, Probert C, Whelan K. Volatile Organic Compounds in Feces Associate With Response to Dietary Intervention in Patients With Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2017 Oct 6. pii: S1542-3565(17)31201-6. doi: 10.1016/j.cgh.2017.09.055.
Staudacher HM, Lomer MCE, Farquharson FM, Louis P, Fava F, Franciosi E, Scholz M, Tuohy KM, Lindsay JO, Irving PM, Whelan K. Low FODMAP diet and probiotics in irritable bowel syndrome: a 2x2 factorial design, randomised, placebo-controlled trial. Gastroenterology. 2017 Oct;153(4):936-947. doi: 10.1053/j.gastro.2017.06.010. Epub 2017 Jun 15.
Tyler TJ, McCarthy NE, Lindsay JO, Stagg AJ, Moser B, Eberl M. Antigen-presenting human γδ T-cells promote intestinal CD4+ T-cell expression of IL-22 and mucosal release of calprotectin. J Immunol. 2017 May 1;198(9):3417-3425. doi: 10.4049/jimmunol.1700003. Epub 2017 Mar 22
Lindsay JO, Allez M, Clark M, Labopin M, Ricart E, Rogler G, Rovira M, Satsangi J, Farge D, Hawkey CJ. Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):399-406. doi: 10.1016/S2468-1253(17)30056-0. Epub 2017 Apr 6
Brooks AJ, Smith PJ, Cohen R, Collins P, Douds A, Forbes V, Gaya DR, Johnston BT, McKiernan PJ, Murray CD, Sebastian S, Smith M, Whitley L, Williams L, Russell RK, McCartney SA, Lindsay JO. UK Guideline on Transition of Adolescent and Young Persons with Chronic Digestive Diseases from Paediatric to Adult Care. Gut. 2017 Jun;66(6):988-1000. doi: 10.1136/gutjnl-2016-313000. Epub 2017 Feb 21.
Giles EM, Sanders TJ, McCarthy NE, Lung J, Pathak M, MacDonald TT, Lindsay JO, Stagg AJ. Regulation of human intestinal T-cell responses by Type 1 Interferon-STAT1 signaling is disrupted in inflammatory bowel disease. Mucosal Immunol, 2017 Jan;10(1):184-193. doi: 10.1038/mi.2016.44. Epub 2016 May 25
Hawkey CJ, (Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G), Rovira M, Satsangi J, Danese S, Russell N, Gribben J, Johnson P, Larghero J, Thieblemont C, Ardizzone S, Dierickx D, Ibatici A, Littlewood T, Onida F, Schanz U, Vermeire S, Colombel JF, Jouet JP, Clark E, Saccardi R, Tyndall A, Travis S, Farge D. Autologous haemopoetic stem cell transplantation for refractory Crohn’s disease: a randomised clinical trial. JAMA. 2015 Dec 15; 314(23):2524-34
McCarthy NE, Hedin CR, Sanders TJ, Amon P, Hoti I, Ayada I, Baji V, Giles EM, Wildemann M, Bashir Z, Whelan K, Sanderson I, Lindsay JO, Stagg AJ. Colonic Vδ2+ T-cells display elevated TNF production and reversible ablation by azathioprine therapy in Crohn’s disease. J Clin Invest. 2015 Aug 3;125(8):3215-25. doi: 10.1172/JCI80840
Hedin C, van der Gast CJ, Rogers GB, Cuthbertson L, McCartney S, Stagg AJ, Lindsay JO, Whelan K. Siblings of Crohn's disease patients exhibit a biologically relevant dysbiosis in the mucosal microbiota. Gut, 2016 Jun;65(6):944-53
SandersTJ, McCarthy NE, Giles EM, Davidson KLM, Haltalli MLR, Hazell S, Lindsay JO, Stagg AJ. Increased Production of Retinoic Acid by Intestinal Macrophages Promotes Their Inflammatory Phenotype in Patients with Crohn’s Disease. Gastroenterology 2014 May;146(5):1278-128
Hedin CR, McCarthy NE, Louis P, Farquharson FM, McCartney S, Taylor K, Prescott NJ, Murrells T, Stagg AJ, Whelan K, Lindsay JO. Altered intestinal microbiota and blood T-cell phenotype are shared by Crohn’s disease patients and their unaffected siblings. Gut, 2014 Oct;63(10):1578-86. doi: 10.1136/gutjnl-2013-306226.
Andreyev HJN, Benton B, Lalji A, Norton C, Mohammed K, Gage H, Pennert K, Lindsay JO. Algorithm driven management of GI symptoms in patients with pelvic radiation disease is highly effective: the ORBIT randomised controlled trial. Lancet, 2013 Dec 21;382(9910):2084-92. doi: 10.1016/S0140-6736(13)61648-7. Epub 2013 Sep 23
McCarthy NE, Bashir Z, Vossenkämpe A, Hedin CR, Giles EM, Bhattacharjee S, Brown SG, Sanders TJ, Whelan K, MacDonald TT, Lindsay JO, Stagg AJ Pro-inflammatory Vδ2+ T-cells Populate the Human Intestinal Mucosa and Enhance IFNγ Production by Colonic αβ T-cells. J Immunol. 2013 Sep 1;191(5):2752-63
Benjamin JL, Hedin CRH, Koutsoumpas A, Ng SC, McCarthy NE , Hart AL, Kamm MA, Sanderson JD, Knight SC, Forbes A, Stagg AJ, Whelan K, Lindsay JO. A randomised, double blind placebo controlled trial of fructo-oligosaccharides in active Crohn’s disease. Gut, 2011 Jul;60(7):923-9
View all James Lindsay's Research Publications at: http://www.researchpublications.qmul.ac.uk
Dr Neil Mcarthy
Dr Amy Lewis
Dr Paul Harrow
Dr Sham Metha